15 April 2014 - Deborah Wilkes
Archived
Safety concerns have prompted the European Union's Pharmacovigilance Risk Assessment Committee (PRAC) to start a review of the expectorants ambroxol and bromhexine, which are the active ingredients of Boehringer Ingelheim's Bisolvon, Mucoangin and Mucosolvan brands.
New to OTCToolbox?
This is available as part of an Annual Subscription to the OTCToolbox website.